BCL10
BCL10 (B-cell lymphoma/leukaemia 10; also CARMEN, CIPER, CLAP, mE10 and c-E10) is a CARD-containing adaptor protein that bridges CARD domain proteins to immune activation. It channels adaptive and innate immune signals towards NF-kappa-B and p38 MAP kinase pathways. Browse Assay Genie's current range of BCL10 research reagents below, or read on for the biology behind the target.
BCL10 plays a key role in both adaptive and innate immune signalling by linking CARD domain-containing proteins to immune activation. It acts downstream of CARD9, CARD11 and CARD14 to activate the NF-kappa-B and MAP kinase p38 pathways (MAPK11, MAPK12, MAPK13 and/or MAPK14), which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Activated CARD proteins homo-oligomerise into a nucleating helical template that recruits BCL10 through CARD-CARD interaction. This promotes BCL10 polymerisation, recruitment of MALT1 and formation of a CBM complex.
The upstream activators are context specific. CARD9 engages BCL10 downstream of C-type lectin receptors, and CARD9-mediated signals are essential for antifungal immunity. CARD11 engages it downstream of the T-cell receptor (TCR) and B-cell receptor (BCR). BCL10 also promotes apoptosis, pro-caspase-9 maturation and NF-kappa-B activation via NIK and IKK. The human BCL10 gene encodes a protein with a caspase recruitment domain (CARD), and alternative splicing yields multiple transcript variants. The protein localises to the perinuclear cytoplasm and to membrane rafts, and mouse and rat both carry a Bcl10 ortholog.
The gene was identified through its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. BCL10 forms a complex with MALT1, which is encoded by another gene translocated in MALT lymphoma. The two proteins are thought to synergise in NF-kappaB activation, and deregulation of either may contribute to the same pathogenetic process leading to malignancy. HGNC classes BCL10 within the caspase recruitment domain containing genes and the CBM complex group. Earlier names include B cell CLL/lymphoma 10.
BCL10 acts downstream of CARD9 and C-type lectin receptors, signalling that is essential for antifungal immunity.
BCL10 relays CARD11 signals from the T-cell and B-cell receptors to NF-kappa-B and p38 MAP kinase activation.
Helical CARD templates nucleate BCL10 polymerisation and MALT1 recruitment, making BCL10 central to CBM complex studies.
BCL10 was identified by translocation in MALT lymphoma, and its deregulation alongside MALT1 may contribute to malignancy.
BCL10 is an adaptor that bridges CARD domain-containing proteins such as CARD9, CARD11 and CARD14 to immune activation. Once recruited, it polymerises, brings in MALT1 and forms a CBM complex, activating NF-kappa-B and p38 MAP kinase pathways. It also promotes apoptosis and pro-caspase-9 maturation.
BCL10 is also called B-cell lymphoma/leukaemia 10, CARMEN, CIPER, CLAP, mE10 and c-E10. Earlier HGNC names include B cell CLL/lymphoma 10. The current HGNC name is BCL10 immune signalling adaptor. Alternative splicing gives multiple transcript variants.
BCL10 was identified through a translocation in MALT lymphoma, and deregulation of BCL10 or MALT1 may contribute to malignancy. Mouse and rat each have a Bcl10 ortholog. Check the datasheet of any product for its validated reactivity.
Other BCL-family proteins and apoptosis regulators that sit alongside BCL10 in lymphoma and cell death research.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O95999; product specifications from Assay Genie datasheets.